Current use and outcomes of cellular therapy: Brazilian Summary Slides – 2026
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e364Keywords:
CAR-T cells, Cancer immunotherapy, Chimeric antigen receptor, Data managementAbstract
Objective: To describe CAR-T cell therapy activity and outcomes reported by Brazilian centers participating in the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO)/Center for International Blood and Marrow Transplant Research (CIBMTR) network between January 2020 and December 2025. Methods: Data from patients who received commercial or academic CAR-T cell therapies in Brazilian centers were extracted from the CIBMTR database. Participating centers reported data through the FormsNet3 platform, allowing standardized collection of patient, disease, and treatment-related variables. Descriptive analyses were performed, and overall survival (OS) was estimated using the Kaplan–Meier method. Results: A total of 219 CAR-T cell infusions were reported. The median age was 57 years (range, 4–83 years). The most common indications were non Hodgkin lymphoma (NHL) (146 patients, 67%), multiple myeloma (MM) (39 patients, 18%), acute lymphoblastic leukemia (ALL) (32 patients, 14%), and chronic lymphocytic leukemia (CLL) (2 patients, 1%). Commercial CAR-T products accounted for 89% of all treatments and were predominantly used for NHL (n = 135) and MM (n = 35). Most deaths were attributed to disease progression or relapse (n = 42), followed by infections (n = 14). After a median followup of 365 days, the 1-year OS was 63% (95% CI, 54–73%) among patients with NHL and 73% (95% CI, 57–93%) among patients with ALL. Conclusion: This report documents the implementation and rapid expansion of CAR-T cell therapy in Brazil among centers reporting to the SBTMO/CIBMTR network. The continued development of this collaborative infrastructure supports national monitoring of CAR-T activity, facilitates outcome assessment, and contributes to quality assurance, benchmarking initiatives, and compliance with national and international regulatory requirements.
References
1. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018 Mar 23;359(6382):1361-5. https://doi.org/10.1126/science.aar6711 DOI: https://doi.org/10.1126/science.aar6711
2. Hemocentro Ribeirão Preto. A história da terapia CAR-T: 60 anos de evolução e pioneirismo em direção à cura do câncer [Internet]. 2023 Jul 11 [cited 2025 Jun 15]. Available from: https://www.hemocentro.fmrp.usp.br/a-historia-da-terapia-car-t-60-anos-de-evolucao-e-pioneirismo-em-direcao-a-cura-do-cancer/
3. Donadel CD, De Santis GC, Gonçalves TE, Pires BG, Palma LC, Gava F, et al. Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil. Bone Marrow Transplant. 2024;59(7):1040-2. https://doi.org/10.1038/s41409-024-02283-6 DOI: https://doi.org/10.1038/s41409-024-02283-6
4. Agência Nacional de Vigilância Sanitária (Anvisa). Anvisa aprova produto de terapia avançada para tratamento de câncer. Brasília (DF): Anvisa; 2022 [cited 2025 Jun 16]. Available from: https://www.gov.br/anvisa/ptbr/assuntos/noticias-anvisa/2022/anvisa-aprova-produto-de-terapia-avancada-para-tratamento-de-cancer
5. Silva CC, Simione AJ, Sabaini PMS, Macedo AV, Neves HRA, Ammi M, et al. Emerging activity of cellular immunotherapy for treatment of cancer in Brazil: report from the Brazilian registry. J Bone Marrow Transplant Cell Ther. 2024;5(2):67-75. https://doi.org/10.46765/2675-374X.2024v5n2p235 DOI: https://doi.org/10.46765/2675-374X.2024v5n2p235
6. Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar OS, Bolon YT, et al. Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy: a report from the CIBMTR. Transplant Cell Ther. 2025;31(8):505-32. https://doi.org/10.1016/j.jtct.2025.05.014 DOI: https://doi.org/10.1016/j.jtct.2025.09.001
7. Sociedade Brasileira de Transplante de Medula Óssea. Terapias CAR-T no Brasil: o que apontam os dados do registro SBTMO/CIBMTR [Internet]. 2025 Jul 4 [cited 2026 Jun 18]. Available from: https://sbtmo.org.br/terapias-car-t-no-brasil-o-que-apontam-os-dados-do-registro-sbtmo-cibmtr/
8. Instituto Nacional de Câncer. Estimativa 2023: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2022 [cited 2026 Jun 18]. Available from: https://www.inca.gov.br/publicacoes/livros/estimativahttps://orcid.org/0000-0003-1579-22932023-incidencia-de-cancer-no-brasil
9. Guerino-Cunha RL, Bessa A, Jansen AM, Oliveira M, Sanku G, Scarabel R, et al. Bridging innovation and equity: the evolving landscape of CAR-T-cell therapy access in Brazil. Front Hematol. 2026;5:1813861. https://doi.org/10.3389/frhem.2026.1813861 DOI: https://doi.org/10.3389/frhem.2026.1813861
10. Clé DV, Donadel CD, Calado RT. A Global View: CAR-T cell in resource-limited regions. Blood Glob Hematol. 2026;2(1):100051. https://doi.org/10.1016/j.bglo.2025.100051 DOI: https://doi.org/10.1016/j.bglo.2025.100051
11. Contreras J, Herschbein L, Mathur N, Guzman ML. Access to CAR-T therapy in Latin America: barriers, gaps, and pathways forward. Semin Immunol. 2026;82:102029. https://doi.org/10.1016/j.smim.2026.102029 DOI: https://doi.org/10.1016/j.smim.2026.102029
12. Licks Attorneys. Judicialization of CAR-T therapies: the crucial role of the judiciary in access to healthcare. 2025 Jan 16 [cited 2026 Jun 18]. Available from: https://www.lickslegal.com/articles/judicialization-of-car-t-therapies-the-crucial-role-of-the-judiciary-in-access-to-healthcare/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Cinthya Corrêa da Silva, Anderson João Simione, Giancarlo Fatobene, Jayr Schmidt Filho, Adriana Seber, Nelson Hamerschlak, João Samuel de Holanda Farias, Vaneuza Araújo Moreira Funke, Phillip Scheinberg, Maria Claudia Rodrigues Moreira, Abel da Costa Neto, Vinicius Campos de Molla, Cilmara Cristina Kuwahara Dumke , Yana Augusta Sarkis Novis, Vanderson Rocha, Fernando Sérgio Blumm Ferreira, Volney Assis Lara Vilela, Grazielly Vargas Grilo, Andresa Lima Melo, Andreza Alice Feitosa Ribeiro, Marcos Paulo Colella, Afonso Celso Vigorito, Marcelo C. Pasquini, Fernando Barroso Duarte
This work is licensed under a Creative Commons Attribution 4.0 International License.
